Immunohistochemical stains are performed and the cells are negative for CD30, while CD3 and CD20 highlight small and mature T and B lymphocytes, respectively. Histologic sections of the right breast capsule show a fibrinous breast capsule with scattered small and …

CD30, also known as TNFRSF8 (tumor necrosis factor receptor superfamily member 8), is a protein receptor that is heavily glycosylated inside the Golgi apparatus, as well as a tumor marker that is found on the surface of specific cells in the body, …

2017年9月8日 · CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma...

CD30 was originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. Cloning and characterization of cDNAs encoding CD30 and its ligand (CD30L) established these proteins as members of the tumor necrosis factor receptor (TNFR) and tumor necrosis factor (TNF) superfamilies, respectively.

In this review, we describe current evidence for anti-CD30 therapy in lymphoma, discuss ongoing controversies and data gaps, and provide perspectives on the direction of anti-CD30 therapy in the future. The development of brentuximab vedotin has altered the treatment approach for patients with cHL.

CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma.

CD30 is a protein made primarily by activated immune cells such as T cells and B cells. Some types of cancers that start from T cells or B cells, such as anaplastic large cell lymphom a and Hodgkin lymphoma also express CD30. The tumour cells in embryonal carcinoma, a type of cancer that often involves the male testis, also make CD30.

Cluster determinant 30 (CD30) has been recognized since the 1980s by a monoclonal antibody (Ki-1) as an epitope of a membrane protein highly expressed on Reed–Sternberg and Hodgkin’s lymphoma cells [9–11] and infrequently on normal blood lymphocytes.

CD30 refers to a TNFR-related surface protein that is expressed by activated T and B cells. It was originally identified as a marker for the tumor cells of Hodgkin's lymphoma. CD30 has also been found on other types of tumors, and a soluble form of CD30 has been detected at high levels in the serum of patients with certain autoimmune diseases.

2000年12月1日 · Defining features consist of a proliferation of predominantly large lymphoid cells with strong expression of the cytokine receptor CD30 and a characteristic growth pattern.